This study explores the potential therapeutic benefits of growth hormone-releasing hormone (GHRH) receptor agonists for cardiac stem cells (CSCs) in heart failure treatment. GHRH-R agonists like JI-38, MR-356, and MR-409 were shown to stimulate CSC proliferation and survival, particularly under oxidative stress, by activating key cell signaling pathways (ERK and
